Abstract
Over the past several years, research has indicated that an individuals genetic makeup strongly influences not only their likelihood of developing depression, but also whether or not they will respond well to a particular antidepressant treatment. Identifying those genes regulating susceptibility to depression will increase our understanding of disease pathophysiology and direct the development of treatments that correct underlying neurobiological pathology related to stress-related psychiatric illnesses. Pharmacologically, the identification of genes regulating treatment response can lead to the design of novel pharmacological treatments and allow for more individualized, rational and successful drug treatments. Unfortunately, complex environmental and genetic mechanisms at play in depression and drug response make the discovery of susceptibility genes in humans quite difficult. Animal models may provide a more desirable system in which to discover susceptibility genes because environmental factors and tests can be regulated and more informative genetic methods can be used. Furthermore, a unique genetic opportunity exists with animal models of depression and antidepressant response because several rodent strains have been identified, or selectively bred, that display exaggerated depressive phenotypes on stress-related behavioral tests or divergent responses to antidepressant drugs. This paper reviews several of these rodent strains and illustrates the genetic strategies available to discover the long-sought susceptibility genes regulating these phenotypes.
Keywords: genetics, depression, antidepressant, rat, mouse, behavior, qtl
Current Pharmaceutical Design
Title: Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics
Volume: 11 Issue: 2
Author(s): James J. Crowley and Irwin Lucki
Affiliation:
Keywords: genetics, depression, antidepressant, rat, mouse, behavior, qtl
Abstract: Over the past several years, research has indicated that an individuals genetic makeup strongly influences not only their likelihood of developing depression, but also whether or not they will respond well to a particular antidepressant treatment. Identifying those genes regulating susceptibility to depression will increase our understanding of disease pathophysiology and direct the development of treatments that correct underlying neurobiological pathology related to stress-related psychiatric illnesses. Pharmacologically, the identification of genes regulating treatment response can lead to the design of novel pharmacological treatments and allow for more individualized, rational and successful drug treatments. Unfortunately, complex environmental and genetic mechanisms at play in depression and drug response make the discovery of susceptibility genes in humans quite difficult. Animal models may provide a more desirable system in which to discover susceptibility genes because environmental factors and tests can be regulated and more informative genetic methods can be used. Furthermore, a unique genetic opportunity exists with animal models of depression and antidepressant response because several rodent strains have been identified, or selectively bred, that display exaggerated depressive phenotypes on stress-related behavioral tests or divergent responses to antidepressant drugs. This paper reviews several of these rodent strains and illustrates the genetic strategies available to discover the long-sought susceptibility genes regulating these phenotypes.
Export Options
About this article
Cite this article as:
Crowley J. James and Lucki Irwin, Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382278
DOI https://dx.doi.org/10.2174/1381612053382278 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis
Current Respiratory Medicine Reviews Releasing the Genie in the Bottle: Molecular Signaling with Hydrogen Sulfide
Current Neurovascular Research Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Renovascular Hypertension: Lesion Detection, Patient Selection, Treatment Options and Results
Current Hypertension Reviews Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Binding Interactions of Forskolin with Human Serum Albumin: Insights from In silico and Spectroscopic Studies
Current Chemical Biology Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design Immunosuppression in Liver Transplantation
Current Drug Targets Kidney CYP450 Enzymes: Biological Actions Beyond Drug Metabolism
Current Drug Metabolism Transition in Infant and Young Child Feeding Practices in India
Current Diabetes Reviews Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
Current Enzyme Inhibition Synthesis and Cytotoxic Evaluation for Some New Dihydropyrimidinone Derivatives for Anticancer Activity
Letters in Drug Design & Discovery Editorial : (Thematic issue: Critical Appraisal of Ischemic Stroke Pathophysiology: Road to Cerebral Resuscitation? Part II)
Current Medicinal Chemistry Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Editorial: Understanding Basic Muscle Electrophysiology While Keeping an Eye on Diseases of the Heart, Lung and Blood
Recent Patents on Cardiovascular Drug Discovery